1.Effect of surgical scope on postoperative fibrosis of knee joints.
Hai-Xiao WU ; Karen-A EGIAZARYAN ; Karen-A EGIAZARYAN ; Karen-A EGIAZARYAN ; Karen-A EGIAZARYAN ; Chao ZHANG
China Journal of Orthopaedics and Traumatology 2018;31(6):587-590
Knee arthrofibrosis is a common complication after surgery, which is one of the key factors affecting the surgical outcome. It often causes the decrease of joint activity, chronic arthralgia, degeneration of cartilage tissues and joint disuse change, which seriously affects the daily life of the patients. How to reduce the occurrence of knee arthrofibrosis is the key to improve the expected effect of surgery, which is also an important problem to solve in clinical medicine; with our team's previous and recent research, we found that the degree of knee arthrofibrosis is closely related to the rang of the surgical. The use of minimally invasive and arthroscopic treatment can reduce the damage to synovial, cartilage and fat pad tissue, at the same time, combining with early postoperative rehabilitation training is the future effective prevention of postoperative arthrofibrosis of knee.
2.Case series of testicular adrenal rest tumours in boys with congenital adrenal hyperplasia: A single centre experience
Karen Sue Wan Leong ; Loo Ling Wu
The Medical Journal of Malaysia 2019;74(1):92-93
Testicular adrenal rest tumours (TART) are aberrant adrenal
tissue within the testes (1). Although benign, they can lead
to obstruction of the seminiferous tubules and infertility in
patients with congenital adrenal hyperplasia (CAH). We
report six boys who developed TART, a complication of CAH.
Diagnosis was confirmed by ultrasound and testicular vein
sampling of elevated 17-hydroxyprogesterone (17-OHP)
levels. Glucocorticoids dosages were increased 1½-2 folds
to suppress size of the aberrant adrenal tissues. Despite
reductions in 17-OHP, the lesions remained unchanged.
Three patients had testis-sparing surgery to excise the TART
and to preserve normal testicular tissues.
3.Spliceosomal genes in the D. discoideum genome: a comparison with those in H. sapiens, D. melanogaster, A. thaliana and S. cerevisiae.
Bing YU ; Petra FEY ; Karen E KESTIN-PILCHER ; Alexei FEDOROV ; Ashwin PRAKASH ; Rex L CHISHOLM ; Jane Y WU
Protein & Cell 2011;2(5):395-409
Little is known about pre-mRNA splicing in Dictyostelium discoideum although its genome has been completely sequenced. Our analysis suggests that pre-mRNA splicing plays an important role in D. discoideum gene expression as two thirds of its genes contain at least one intron. Ongoing curation of the genome to date has revealed 40 genes in D. discoideum with clear evidence of alternative splicing, supporting the existence of alternative splicing in this unicellular organism. We identified 160 candidate U2-type spliceosomal proteins and related factors in D. discoideum based on 264 known human genes involved in splicing. Spliceosomal small ribonucleoproteins (snRNPs), PRP19 complex proteins and late-acting proteins are highly conserved in D. discoideum and throughout the metazoa. In non-snRNP and hnRNP families, D. discoideum orthologs are closer to those in A. thaliana, D. melanogaster and H. sapiens than to their counterparts in S. cerevisiae. Several splicing regulators, including SR proteins and CUG-binding proteins, were found in D. discoideum, but not in yeast. Our comprehensive catalog of spliceosomal proteins provides useful information for future studies of splicing in D. discoideum where the efficient genetic and biochemical manipulation will also further our general understanding of pre-mRNA splicing.
Alternative Splicing
;
Animals
;
Arabidopsis
;
genetics
;
Dictyostelium
;
genetics
;
Drosophila melanogaster
;
genetics
;
Genome, Protozoan
;
Humans
;
Phylogeny
;
Ribonucleoproteins, Small Nuclear
;
classification
;
genetics
;
Saccharomyces cerevisiae
;
genetics
;
Spliceosomes
;
genetics
;
metabolism
4.Expression and function of MCP-1 and its receptor in wAMD model mouse
Quan ZHOU ; Lin XIAO ; Jing-Mei XU ; Bing XU ; Karen WU ; Jing LIU ; Yan LU ; Li-Qun CHU
Chinese Journal of Clinical and Experimental Pathology 2018;34(1):32-36
Purpose To detect the expression and the function of MCP-1 and its receptor CCR2 in wet agerelated macular degenerative (wAMD) model mouse retina. Methods C57BL/6J mouse were enrolled into the study. Model mouse of wAMD was induced with laser. Frozen sections were prepared for histopathological tests. Immunofluorescence study for MCP-1 and CCR2 was carried out. Co-expression study for CCR2/ CDllb or CCR2/CD68 was carried out. Total protein and total mRNA from the eyes of both wAMD and wild type mouse were extracted. The expression of mRNA and protein of MCP-1 and CCR2 in the eyes were determined by reverse transcription-poly-merase chain reaction (RT-PCR) and Western blots test, respectively. Results In wild type mouse, both MCP-1 and its receptor CCR2 were not detected in the retina. However in wAMD mouse, an obvious up-regulated MCP-1 and CCR2 expression was seen in the retinal pigment epithelium (RPE) cells accompanied with the increased expression of their mRNA and protein. The co-expression study showed that CCR2 co-ex-pressed with CDllb, but not with CD68. Conclusion MCP-1 and its receptor CCR2 may play a role in the wAMD through stimulation of microglia.
5.Diverse genetic spectrum among patients who met the criteria of hereditary breast, ovarian and pancreatic cancer syndrome
Po-Han LIN ; Yun-Wen TIEN ; Wen-Fang CHENG ; Ying-Cheng CHIANG ; Chien-Huei WU ; Karen YANG ; Chiun-Sheng HUANG
Journal of Gynecologic Oncology 2023;34(5):e66-
Objective:
Genetic high-risk assessment combines hereditary breast, ovarian and pancreatic cancer into one syndrome. However, there is a lack of data for comparing the germline mutational spectrum of the cancer predisposing genes between these three cancers.
Methods:
Patients who met the criteria of the hereditary breast, ovarian and pancreatic cancer were enrolled and received multi-gene sequencing.
Results:
We enrolled 730 probands: 418 developed breast cancer, 185 had ovarian cancer, and 145 had pancreatic cancer. Out of the 18 patients who had two types of cancer, 16 had breast and ovarian cancer and 2 had breast and pancreatic cancer. A total of 167 (22.9%) patients had 170 mutations. Mutation frequency in breast, ovarian and pancreatic cancer was 22.3%, 33.5% and 17.2%, respectively. The mutation rate was significantly higher in patients with double cancers than those with a single cancer (p<0.001). BRCA1 and BRCA2 were the most dominant genes associated with hereditary breast and ovarian cancer, whereas ATM was the most prevalent gene related to hereditary pancreatic cancer. Genes of hereditary colon cancer such as lynch syndrome were presented in a part of patients with pancreatic or ovarian cancer but seldom in those with breast cancer. Families with a history of both ovarian and breast cancer were associated with a higher mutation rate than those with other histories.
Conclusion
The mutation spectrum varies across the three cancer types and family histories. Our analysis provides guidance for physicians, counsellors, and counselees on the offer and uptake of genetic counseling.
6.Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
Chi-Ho LEE ; Mei-Zhen WU ; David Tak-Wai LUI ; Darren Shing-Hei CHAN ; Carol Ho-Yi FONG ; Sammy Wing-Ming SHIU ; Ying WONG ; Alan Chun-Hong LEE ; Joanne King-Yan LAM ; Yu-Cho WOO ; Karen Siu-Ling LAM ; Kelvin Kai-Hang YIU ; Kathryn Choon-Beng TAN
Diabetes & Metabolism Journal 2022;46(6):843-854
Background:
Insulin-treated patients with long duration of type 2 diabetes mellitus (T2DM) are at increased risk of ketoacidosis related to sodium-glucose co-transporter 2 inhibitor (SGLT2i). The extent of circulating ketone elevation in these patients remains unknown. We conducted this study to compare the serum ketone response between dapagliflozin, an SGLT2i, and sitagliptin, a dipeptidyl peptidase-4 inhibitor, among insulin-treated T2DM patients.
Methods:
This was a randomized, open-label, active comparator-controlled study involving 60 insulin-treated T2DM patients. Participants were randomized 1:1 for 24-week of dapagliflozin 10 mg daily or sitagliptin 100 mg daily. Serum β-hydroxybutyrate (BHB) levels were measured at baseline, 12 and 24 weeks after intervention. Comprehensive cardiometabolic assessments were performed with measurements of high-density lipoprotein cholesterol (HDL-C) cholesterol efflux capacity (CEC), vibration-controlled transient elastography and echocardiography.
Results:
Among these 60 insulin-treated participants (mean age 58.8 years, diabetes duration 18.2 years, glycosylated hemoglobin 8.87%), as compared with sitagliptin, serum BHB levels increased significantly after 24 weeks of dapagliflozin (P=0.045), with a median of 27% increase from baseline. Change in serum BHB levels correlated significantly with change in free fatty acid levels. Despite similar glucose lowering, dapagliflozin led to significant improvements in body weight (P=0.006), waist circumference (P=0.028), HDL-C (P=0.041), CEC (P=0.045), controlled attenuation parameter (P=0.007), and liver stiffness (P=0.022). Average E/e’, an echocardiographic index of left ventricular diastolic dysfunction, was also significantly lower at 24 weeks in participants treated with dapagliflozin (P=0.037).
Conclusion
Among insulin-treated T2DM patients with long diabetes duration, compared to sitagliptin, dapagliflozin modestly increased ketone levels and was associated with cardiometabolic benefits.
7.Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2.
Saba R ALIYARI ; Amir Ali GHAFFARI ; Olivier PERNET ; Kislay PARVATIYAR ; Yao WANG ; Hoda GERAMI ; Ann-Jay TONG ; Laurent VERGNES ; Armin TAKALLOU ; Adel ZHANG ; Xiaochao WEI ; Linda D CHILIN ; Yuntao WU ; Clay F SEMENKOVICH ; Karen REUE ; Stephen T SMALE ; Benhur LEE ; Genhong CHENG
Acta Pharmaceutica Sinica B 2022;12(4):1624-1635
SARS-CoV-2 is an emerging viral pathogen and a major global public health challenge since December of 2019, with limited effective treatments throughout the pandemic. As part of the innate immune response to viral infection, type I interferons (IFN-I) trigger a signaling cascade that culminates in the activation of hundreds of genes, known as interferon stimulated genes (ISGs), that collectively foster an antiviral state. We report here the identification of a group of type I interferon suppressed genes, including fatty acid synthase (FASN), which are involved in lipid metabolism. Overexpression of FASN or the addition of its downstream product, palmitate, increased viral infection while knockout or knockdown of FASN reduced infection. More importantly, pharmacological inhibitors of FASN effectively blocked infections with a broad range of viruses, including SARS-CoV-2 and its variants of concern. Thus, our studies not only suggest that downregulation of metabolic genes may present an antiviral strategy by type I interferon, but they also introduce the potential for FASN inhibitors to have a therapeutic application in combating emerging infectious diseases such as COVID-19.